Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DXR NASDAQ:KRMD NASDAQ:LUNG NASDAQ:PDEX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXRDaxor$9.50+1.6%$8.50$6.55▼$10.00$45.98M-0.075,969 shs612 shsKRMDKORU Medical Systems$3.79-0.4%$3.13$1.86▼$5.05$174.64M0.52143,655 shs22,054 shsLUNGPulmonx$2.69-1.5%$3.13$2.50▼$9.37$108.30M0.45304,596 shs97,877 shsPDEXPro-Dex$47.64-0.1%$44.03$17.20▼$70.26$155.16M0.1936,634 shs33,508 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXRDaxor-5.17%-3.11%+1.08%+21.27%+6.49%KRMDKORU Medical Systems+3.54%+3.26%+23.38%+65.94%+52.00%LUNGPulmonx+3.41%+1.49%-13.88%-49.72%-57.67%PDEXPro-Dex+3.18%+9.41%+11.14%-18.66%+166.42%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDXRDaxorN/AN/AN/AN/AN/AN/AN/AN/AKRMDKORU Medical Systems1.595 of 5 stars2.53.00.00.00.62.50.6LUNGPulmonx3.0047 of 5 stars3.33.00.00.02.03.30.6PDEXPro-Dex2.4625 of 5 stars2.52.00.00.02.81.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDXRDaxor 3.00Buy$25.00163.16% UpsideKRMDKORU Medical Systems 3.00Buy$4.5018.89% UpsideLUNGPulmonx 2.63Moderate Buy$11.53328.44% UpsidePDEXPro-Dex 3.00Buy$56.0017.56% UpsideCurrent Analyst Ratings BreakdownLatest DXR, PDEX, KRMD, and LUNG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025PDEXPro-DexAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$54.00 ➝ $56.005/22/2025LUNGPulmonxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$6.50 ➝ $4.155/8/2025KRMDKORU Medical SystemsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$4.50 ➝ $3.505/1/2025LUNGPulmonxCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $15.005/1/2025LUNGPulmonxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$10.00 ➝ $9.005/1/2025LUNGPulmonxD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.00(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDXRDaxorN/AN/AN/AN/AN/AN/AKRMDKORU Medical Systems$33.65M5.19N/AN/A$0.37 per share10.23LUNGPulmonx$83.79M1.29N/AN/A$2.17 per share1.24PDEXPro-Dex$64.12M2.42$0.99 per share48.27$9.03 per share5.28Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDXRDaxorN/AN/A0.00∞N/AN/AN/AN/AN/AKRMDKORU Medical Systems-$6.07M-$0.11N/AN/AN/A-15.09%-30.43%-19.41%8/6/2025 (Estimated)LUNGPulmonx-$56.39M-$1.44N/AN/AN/A-65.27%-63.69%-34.94%7/30/2025 (Estimated)PDEXPro-Dex$2.13M$2.8016.9923.12N/A14.61%29.08%16.19%9/4/2025 (Estimated)Latest DXR, PDEX, KRMD, and LUNG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025KRMDKORU Medical Systems-$0.03N/AN/AN/A$9.46 millionN/A7/30/2025Q2 2025LUNGPulmonx-$0.40N/AN/AN/A$23.46 millionN/A5/7/2025Q1 2025KRMDKORU Medical Systems-$0.02-$0.03-$0.01-$0.03$8.86 million$9.64 million5/7/2025Q1 2025LUNGPulmonx-$0.37-$0.36+$0.01-$0.36$22.03 million$22.54 million5/1/2025Q3 2025PDEXPro-Dex$0.47$0.98+$0.51$0.98$17.70 million$17.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDXRDaxorN/AN/AN/AN/AN/AKRMDKORU Medical SystemsN/AN/AN/AN/AN/ALUNGPulmonxN/AN/AN/AN/AN/APDEXPro-DexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDXRDaxorN/AN/AN/AKRMDKORU Medical Systems0.012.442.02LUNGPulmonx0.384.974.29PDEXPro-Dex0.282.731.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDXRDaxor1.34%KRMDKORU Medical Systems58.60%LUNGPulmonx91.04%PDEXPro-Dex15.28%Insider OwnershipCompanyInsider OwnershipDXRDaxor59.50%KRMDKORU Medical Systems20.60%LUNGPulmonx6.80%PDEXPro-Dex47.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDXRDaxor374.84 million1.96 millionNot OptionableKRMDKORU Medical Systems8046.14 million36.64 millionOptionableLUNGPulmonx25040.26 million37.52 millionOptionablePDEXPro-Dex1403.26 million1.71 millionNot OptionableDXR, PDEX, KRMD, and LUNG HeadlinesRecent News About These CompaniesNew Strong Buy Stocks for July 1stJuly 1, 2025 | zacks.comBest Value Stocks to Buy for July 1stJuly 1, 2025 | zacks.comPro-Dex, Inc. (PDEX) Stock Price, Quote, News & Analysis - Seeking AlphaJune 27, 2025 | seekingalpha.comInvestors Shouldn't Overlook The Favourable Returns On Capital At Pro-Dex (NASDAQ:PDEX)June 23, 2025 | finance.yahoo.comHere is Why Growth Investors Should Buy ProDex (PDEX) NowJune 17, 2025 | zacks.comProDex (PDEX) Upgraded to Buy: Here's WhyJune 17, 2025 | zacks.comAre Pro-Dex, Inc.'s (NASDAQ:PDEX) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?May 20, 2025 | finance.yahoo.comPro-Dex: Crash After Strong Earnings Leads To A Buying OpportunityMay 5, 2025 | seekingalpha.comHere's Why Pro-Dex (NASDAQ:PDEX) Has Caught The Eye Of InvestorsMay 4, 2025 | uk.finance.yahoo.comPro-Dex, Inc. (PDEX) Q3 Earnings Surpass EstimatesMay 1, 2025 | zacks.comPro-Dex, Inc. Announces Fiscal 2025 Third Quarter and Nine-Month ResultsMay 1, 2025 | accessnewswire.comAProDex (PDEX) Moves 5.1% Higher: Will This Strength Last?April 25, 2025 | zacks.comTake the Zacks Approach to Beat the Markets: Pro-Dex, Brookdale Senior Living, Coca-Cola in FocusApril 21, 2025 | zacks.comProDex (PDEX) Surges 7.4%: Is This an Indication of Further Gains?April 3, 2025 | zacks.comPro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot Sells 842 SharesApril 2, 2025 | insidertrades.comPro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot Sells 836 SharesApril 1, 2025 | insidertrades.comInsider Selling: Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells 3,096 Shares of StockMarch 28, 2025 | insidertrades.comInsider Selling: Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells 5,151 Shares of StockMarch 18, 2025 | insidertrades.comWith 38% ownership in Pro-Dex, Inc. (NASDAQ:PDEX), hedge funds investors have a lot riding on the businessMarch 11, 2025 | finance.yahoo.comProDex (PDEX) Upgraded to Strong Buy: Here's What You Should KnowFebruary 28, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDXR, PDEX, KRMD, and LUNG Company DescriptionsDaxor NASDAQ:DXR$9.50 +0.15 (+1.60%) As of 11:47 AM EasternDaxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.KORU Medical Systems NASDAQ:KRMD$3.78 -0.02 (-0.39%) As of 01:18 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.KORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey.Pulmonx NASDAQ:LUNG$2.69 -0.04 (-1.47%) As of 01:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.Pro-Dex NASDAQ:PDEX$47.64 -0.07 (-0.14%) As of 01:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound Rises as Short Sellers Exit and AI Demand Grows Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Palantir’s Revenue Surge to $1B: Growth vs. Valuation Chime Financial: Analysts Ring In—And It’s a Buy Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
